Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tango TherapeuticsTNGX 54 Debt-to-Equity is 0.03 as of Jun. 2026, which is 80% below its 10-year median of 0.15. GuruFocus rates TNGX with a GF Score™ of 54/100 and a GF Value™ of $9.75 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 962 Biotechnology companies, Tango Therapeutics ranks better than 81.19% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Tango Therapeutics's Debt-to-Equity or its related term are showing as below:
TNGX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.15 Max: 0.26
Current: 0.03
During the past 6 years, the highest Debt-to-Equity Ratio of Tango Therapeutics was 0.26. The lowest was 0.00. And the median was 0.15.
TNGX's Debt-to-Equity is ranked better than 81.19% of 962
companies
in the Biotechnology industry
Industry Median: 0.16
vs TNGX: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Tango Therapeutics Debt-to-Equity Related Terms
Tango Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Tango Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TNGX vs IDYA, LEGN, DNLI: Debt-to-Equity Comparison
For the Biotechnology subindustry, Tango Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tango Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tango Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Tango Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tango Therapeutics (TNGX) has a Debt-to-Equity of 0.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tango Therapeutics and its competitors. This is 80% below median its historical median of 0.15. According to the industry distribution chart, Tango Therapeutics ranks #181 out of 962 companies in the Biotechnology industry, placing it in the top 18.8%.
Is Tango Therapeutics' Debt-to-Equity too high?
Tango Therapeutics' current Debt-to-Equity of 0.03 is 80% below median its 10-year median of 0.15. The Biotechnology industry median Debt-to-Equity is 0.16. Tango Therapeutics' value of 0.03 is 81.3% below this industry median. Based on the distribution chart, Tango Therapeutics ranks #181 out of 962 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tango Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tango Therapeutics' Debt-to-Equity compare to IDYA and LEGN?
According to the Biotechnology industry distribution chart, Tango Therapeutics ranks #181 out of 962 companies for Debt-to-Equity. This places Tango Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Tango Therapeutics' value of 0.03 is 81.3% below this benchmark. While the company's 10-year median is 0.15 vs. the industry median of 0.16, Tango Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tango Therapeutics's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tango Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tango Therapeutics's current Debt-to-Equity is 0.03, which is 80% below median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tango Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Tango Therapeutics (TNGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.75, compared to a current price of $22.70 — trading 132.8% above its estimated fair value. The current Debt-to-Equity is 0.03, which is 80% below median its 10-year median of 0.15 and 81.3% below the Biotechnology industry median of 0.16. Tango Therapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Tango Therapeutics (TNGX), the current Debt-to-Equity is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tango Therapeutics (TNGX) Overvalued in 2026?
Based on GuruFocus' analysis, Tango Therapeutics stock appears to be overvalued.
The current stock price of $22.70 is trading 132.8% above its estimated GF Value™ of $9.75.
GuruFocus considers Tango Therapeutics to be Significantly Overvalued.
Key valuation signals for TNGX:
Debt-to-Equity: 0.03 (80% below median its 10-year median of 0.15)
GF Value™: $9.75 vs. price of $22.70 (132.8% above fair value)
Industry Position: 81.3% below the Biotechnology median (#181 of 962)
No single metric tells the full story. See the TNGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
54GF Score
Get the complete analysis for TNGX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNGX has been successfully added to your 
